Abstract
Hepatocellular carcinoma(HCC)is responsible for a significant number of cancer-related deaths worldwide and its incidence is increasing.Locoregional treatments,which are precision procedures guided by imaging to specifically target liver tumors,play a critical role in the management of a substantial portion of HCC cases.These therapies have become an essential element of the HCC treatment landscape,with transarterial chemoembolization(TACE)being the treatment of choice for patients with intermediate to advanced stages of the disease.Other locoregional therapies,like radiofrequency ablation,are highly effective for small,early-stage HCC.Nevertheless,the advent of targeted immunotherapy has challenged these established treatments.Tyrosine kinase inhibitors(TKIs)and immune checkpoint inhibitors(ICIs)have shown remarkable efficacy in clinical settings.However,their specific uses and the development of resistance in subsequent treatments have led clinicians to reevaluate the future direction of HCC therapy.This review concentrates on the distinct features of both systemic and novel locoregional therapies.We investigate their effects on the tumor microenvironment at the molecular level and discuss how targeted immunotherapy can be effectively integrated with locoregional therapies.We also examine research findings from retrospective studies and randomized controlled trials on various combined treatment regimens,assessing their validity to determine the future evolution of locoregional therapies within the framework of personalized,comprehensive treatment.
NETL
NSTL
万方数据